User login
Key clinical point: Independent of loading dose, secukinumab provided low rates of radiographic progression over 2 years in patients with active psoriatic arthritis (PsA).
Major finding: At 2 years, proportions of patients with no radiographic progression with secukinumab 300 mg, 150 mg, and 150 mg no load were 89.5%, 82.3%, and 81.1%, respectively. Radiographic damage assessed by the mean change from baseline in van der Heijde-modified total Sharp score was 0.10±1.74, 0.52±2.66, and 0.41±2.20 in the secukinumab 300 mg, 150 mg, and 150 mg no-load groups, respectively.
Study details: Findings are end-of-study results from the phase 3 FUTURE 5 trial including 783 patients with active PsA who were randomly assigned to receive secukinumab 300 mg, secukinumab 150 mg with/without loading dose, or placebo for 4 consecutive weeks and every 4 weeks subsequently.
Disclosures: This study was funded by Novartis Pharma. Some of the authors declared receiving research grants and consulting and speaker fees from various sources including Novartis. Four authors declared being past or current employees and/or shareholders of Novartis.
Source: Mease PJ et al. RMD Open. 2021 Jul 30. doi: 10.1136/rmdopen-2021-001600.
Key clinical point: Independent of loading dose, secukinumab provided low rates of radiographic progression over 2 years in patients with active psoriatic arthritis (PsA).
Major finding: At 2 years, proportions of patients with no radiographic progression with secukinumab 300 mg, 150 mg, and 150 mg no load were 89.5%, 82.3%, and 81.1%, respectively. Radiographic damage assessed by the mean change from baseline in van der Heijde-modified total Sharp score was 0.10±1.74, 0.52±2.66, and 0.41±2.20 in the secukinumab 300 mg, 150 mg, and 150 mg no-load groups, respectively.
Study details: Findings are end-of-study results from the phase 3 FUTURE 5 trial including 783 patients with active PsA who were randomly assigned to receive secukinumab 300 mg, secukinumab 150 mg with/without loading dose, or placebo for 4 consecutive weeks and every 4 weeks subsequently.
Disclosures: This study was funded by Novartis Pharma. Some of the authors declared receiving research grants and consulting and speaker fees from various sources including Novartis. Four authors declared being past or current employees and/or shareholders of Novartis.
Source: Mease PJ et al. RMD Open. 2021 Jul 30. doi: 10.1136/rmdopen-2021-001600.
Key clinical point: Independent of loading dose, secukinumab provided low rates of radiographic progression over 2 years in patients with active psoriatic arthritis (PsA).
Major finding: At 2 years, proportions of patients with no radiographic progression with secukinumab 300 mg, 150 mg, and 150 mg no load were 89.5%, 82.3%, and 81.1%, respectively. Radiographic damage assessed by the mean change from baseline in van der Heijde-modified total Sharp score was 0.10±1.74, 0.52±2.66, and 0.41±2.20 in the secukinumab 300 mg, 150 mg, and 150 mg no-load groups, respectively.
Study details: Findings are end-of-study results from the phase 3 FUTURE 5 trial including 783 patients with active PsA who were randomly assigned to receive secukinumab 300 mg, secukinumab 150 mg with/without loading dose, or placebo for 4 consecutive weeks and every 4 weeks subsequently.
Disclosures: This study was funded by Novartis Pharma. Some of the authors declared receiving research grants and consulting and speaker fees from various sources including Novartis. Four authors declared being past or current employees and/or shareholders of Novartis.
Source: Mease PJ et al. RMD Open. 2021 Jul 30. doi: 10.1136/rmdopen-2021-001600.